Changing the double-pigtail stent by a new suture stent to improve patient’s quality of life: a prospective study by Benoît Vogt et al.
1 3
World J Urol (2015) 33:1061–1068
DOI 10.1007/s00345-014-1394-2
INVITED REVIEW
Changing the double‑pigtail stent by a new suture stent 
to improve patient’s quality of life: a prospective study
Benoît Vogt · Arnaud Desgrippes · 
François‑Noël Desfemmes 
Received: 6 July 2014 / Accepted: 24 August 2014 / Published online: 12 September 2014 
© The Author(s) 2014. This article is published with open access at Springerlink.com
stent. The scores of the two groups fitted with a PSS were not 
significantly different at Day 15 post-placement. Unexpect-
edly, following PSS implantation, we observe a clear dilation 
of the ureter without inflammation around the suture.
Conclusions The PSS significantly decreases stent’s 
symptoms and constitutes a medical advance in the domain 
of ureteral stent tolerance.
Keywords Stent · Quality of life · Suture · Thread · 
Dilation · Ureter
Introduction
Double-pigtail stents are frequently implanted in the ure-
ter in urological practice. However, they are poorly toler-
ated, severely impairing the quality of life of patients [1, 
2]. Several studies have clearly described symptoms asso-
ciated with their use: urinary frequency, urgency, dysuria, 
incontinence, hematuria, incomplete emptying, a feeling 
of pelvic heaviness, and lumbar pain. These symptoms are 
due largely to the bladder irritation caused by the stent [3]. 
It has been suggested that changes to the size, form, and 
composition of stents could decrease discomfort. Indeed, 
by decreasing the amount of material in the bladder, it may 
be possible to attenuate the symptoms [3].
We developed a pigtail suture stent (PSS), which has 
been used since December 2010 in 295 patients. In this 
innovative PSS, the lower part of the stent is replaced by 
a 0.3F thread of suture. Only the renal and ureteral parts of 
the stent are retained and are extended by a thin tail end-
ing in a suture (Fig. 1). Whether the obstruction is due to a 
stone, an ureteropelvic junction syndrome, or ureteral ste-
nosis, the upper, unmodified part of the stent facilitates the 
passage of urine around the obstacle.
Abstract 
Purpose Double-pigtail stent intolerance reduces 
patient’s quality of life. By decreasing the amount of mate-
rial within the bladder, it should be possible to attenuate 
stent’s symptoms. We evaluated the tolerance of a new stent 
with a dedicated questionnaire.
Methods The major innovation of the pigtail suture stent 
(PSS) is in the replacement of the lower part of the double-
pigtail stent with a 0.3F suture. A total of 79 consecutive 
patients agreed to be fitted with a PSS. The double-pigtail 
stents of 24 patients complaining strongly of symptoms were 
replaced with PSS (group 1), and 55 other patients were fitted 
directly with the PSS after an ureteral endoscopic interven-
tion (group 2). The questionnaire was prospectively adminis-
tered to patients at baseline and Day 15 post-placement.
Results All questionnaires were returned. In group 1, the 
replacement of the double-pigtail stent with a PSS signifi-
cantly decreased urinary symptom scores (35.2 ± 7.5 vs. 
23.6 ± 5.4; p = 2 × 10−6) and pain scores (11.0 ± 3.9 vs. 
4.9 ± 3.1; p = 1 × 10−7). In group 1, the baseline scores were 
not significantly different from those of control group with 
double-pigtail stent. In group 2, the urinary scores with PSS 
were significantly different from those of baseline without 
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In a previous retrospective study with 56 patients fit-
ted with a non-profiled PSS, we found that tolerance was 
improved, with surprisingly good levels of bladder toler-
ance, but frequent anterior flank discomfort. This discom-
fort seemed to be due to irritation caused by the lower 
part of the stent, which was sectioned manually and was 
unmodified. The answer rate to the questionnaires was 
75 % [4]. In December 2012, the lower end of the stent was 
sculpted and thinned, like a radical or rootlet, to prevent 
irritation of the ureter. This clearly increased PSS toler-
ance. Furthermore, we discovered fortuitously that PSS had 
other surprising properties. We observed clear dilation of 
the ureter intubated with the sutures.
In this study, we evaluate the effect of the PSS with the 
innovative profiled tail on urinary symptoms and pain by 
using a dedicated questionnaire.
Patients and methods
Technique: construction, implantation, and ablation of the 
PSS
The short model: A polyurethane double-pigtail stent (Dou-
ble loop ureteral stents 7F 26 cm, Coloplast) is sectioned 
perpendicularly to the main axis, 10 cm from the renal 
loop. The sectioned part is then cut parallel to the main 
axis, to give two equal parts, each 3 cm long, to form the 
tail. At the upper end of the tail, this cutting results in a 
smooth, lateral beveled edge. The tail is then thinned out 
toward the lower end, where its diameter should not exceed 
0.5 mm. A polypropylene suture (Ethicon monofilament 
polypropylene suture; gauge size U.S.P.1; 0.1–0.15 mm; 
5–0) perforates the end of the tail and then the stent, above 
the beveled edge. A knot is tied at the beveled edge, and the 
tail of the PSS consists of two 0.3F sutures. Each suture is 
about 20 cm long. A knot was sometimes tied at the lower 
end of the sutures. This PSS has a total length of 30 cm.
The long model: a polyurethane double-pigtail tumor 
stent (Double loop ureteral stent Vortek Tumor Stent 7F 
26 cm, Coloplast) is sectioned perpendicularly, ensuring 
that the stent remains long enough to descend 3 cm below 
the obstructive ureteral stenosis or stone; it is about 20 cm 
long. A tail is cut, and a suture only 10 cm long is passed 
through the stent, as described above.
The intervention is carried out under general or regional 
anesthesia. The pigtail is placed in the kidney, as for a nor-
mal double-pigtail stent under direct vision through the 
cystoscope and fluoroscopic guidance, but a sufficiently 
long ureteral stent is used to make up for the shortness of 
the pushing device. A stent (Open-End Flexi-Tip Ureteral 
Catheter, 5F, 70 cm, Cook Medical) was placed upside 
down on the wire guide to look like the end of the usual 
pusher. Approximately 50 cm is needed to push the PSS. 
The sutures were left in the bladder. PSS was withdrawn 
under local or general anesthesia, with the aid of flexible 
cystoscopy and forceps (Karl Storz—Endoskope, Biopsy 
Forceps, double action jaws, 7F, length 40 cm, 27175A), by 
simply pulling on the sutures. The knot at the lower end of 
the sutures could facilitate stent removal.
Fig. 1  Anatomical position and manually cut of the PSS. A Short 
PSS implanted for a ureteral obstruction, with stent prolongation by 
a bladder suture. B Long PSS for lumbar-iliac or obstructive upper 
pelvic ureteral stenosis or stone, with intubation of the obstruction by 
the stent and then by bladder suture prolongation. a Obstruction by 
stone in the ureter or at the ureteropelvic junction. b Obstruction due 
to a stone or a compressive tumor in the ureter. C The characteristic 
innovation of this stent is that the lower part of the stent was replaced 
with a 0.3F suture. The thinning out of the lower end appears to limit 
the catching of the stent on the ureter during breathing movements. 
Without suture, the short model is 10 cm long and the long model is 
20 cm long
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Patients and groups
From January to July 2013 in a single institution, 79 con-
secutive patients agreed to be fitted with the PSS, with the 
aim of attenuating their urinary symptoms. Twenty-four of 
these patients complained strongly of symptoms associated 
with a double-pigtail stent already fitted (Double loop ure-
teral stents 7F 26 cm; Coloplast) and sought relief from these 
symptoms. Their stents were replaced with the PSS (group 
1). The other 55 patients received a PSS directly after ure-
teral endoscopy (group 2). Ten patients fitted with double-
pigtail stent for pelvic stone were evaluated as control group.
Questionnaires
A French translation of the ureteral stent symptoms ques-
tionnaire was used to evaluate stent tolerance [5, 6]. We 
have extracted exactly the 11 questions relating to urinary 
symptoms (U1-11, total score of 11–56). We used five 
questions relating to pain (P1-3 and P7-8, total score of 
2–17) and one question relating to impact on work (W5, 
score of 1–5). The questionnaire was administered to the 
79 patients at baseline and Day 15 post-placement. The 
questionnaire was administered to the control group at Day 
15 post-placement. The questionnaire was administered to 
the patients of group 1 at baseline with double-pigtail stent 
and Day 15 after PSS placement. The questionnaire was 
administered to the patients of group 2 at baseline without 
stent and Day 15 after PSS placement. Ten patients were 
evaluated as control group with double-pigtail stent at Day 
15 post-placement. The patient has completed the question-
naire. Our questionnaire was approved by French Ethical 
Committee (IRB registration 00001072).
Statistical analysis
The data are presented as mean ± SD. Kruskal–Wallis test 
and χ2 test were used to check the comparability of the 
groups. A paired or two-tailed Student’s t test and Fisher’s 
exact test were used to compare scores between groups. 
Values of p < 0.05 were considered significant.
Results
All questionnaires were returned. Sixty-four patients (81.0 %) 
had obstructive ureteral stones, 3 patients (3.8 %) had obstruc-
tion of the ureteropelvic junction, and 12 patients (15.2 %) had 
obstructive stenosis in the iliac or pelvic ureter. Twenty-three 
patients received the long model of the PSS for malignant 
obstructive ureteral stenosis or distal stone. Age, sex, weight, 
height, side, procedures, and cause of the derivation are sum-
marized in Table 1. The three groups were comparable.
Technical results
In group 1, the mean duration of stenting before PSS was 
17.3 ± 10.2 days. In all cases, the PSS gave effective renal 
drainage. No difficulty in the placement of the PSS was 
encountered. No ureteral stricture induced by the PSS was 
reported in our patients. The PSS was replaced by double-
pigtail stent after laparoscopy for ureteropelvic junction. 
Twelve patients with ureteral stenosis still have implanted 
PSS. No calcification was observed on the sutures 6 months 
after stenting. The stent was removed from the other 
patients, after 58.8 ± 24.6 days.
Forty-nine patients undergoing repeat surgery for endo-
scopic stone treatment after PSS implantation presented 
clear dilation of the ureteral meatus and the ureter. This 
dilatation facilitated the introduction of a 12F rigid uretero-
scope or the sheath of a flexible ureteroscope, without the 
need for further enlargement.
Table 1  Patient characteristics












 Mean ± SD 58.9 ± 15.1 60.0 ± 15.0 53.6 ± 13.1 0.44
Male/female 14/10 34/21 7/3 0.82
Weight (kg)
 Mean ± SD 71.2 ± 15.8 77.0 ± 15.2 80.0 ± 15.3 0.27
Height (cm)
 Mean ± SD 165.2 ± 10.9 166.5 ± 9.0 171.1 ± 9.1 0.40
Side (R/L) 16/8 29/26 6/4 0.51
Indication for stenting
 Proximal stone 15 35 0








 Stenting alone 6 13 0
 SWL 2 6 0
 Urine  
alkalinization
1 2 0
 SWL and  
ureteroscopy
12 12 0
 Ureteroscopy 3 22 10
Stent removal
 Flexible  
cystoscopy
4 15 10
 Ureteroscopy 14 31 0
 Laparoscopy 1 2 0
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During stent removal, the bladder sutures were found 
to have migrated into the urethra in 12 men and 1 woman. 
This trans-sphincter migration of the sutures had no conse-
quences for continence. Three of the PSS had to be with-
drawn under ureteroscopy, because the sutures were cut too 
short and had migrated into the ureter. In these three cases, 
stent removal through the ureter was easy without the fur-
ther enlargement of meatus.
Functional results
The differences in urinary and pain symptoms between 
groups 1 and 2 are summarized in Table 2. In group 1, 
scores for urinary symptoms (35.2 ± 7.5 vs. 23.6 ± 5.4; 
p = 2 × 10−6) and pain scores (11.0 ± 3.9 vs. 4.9 ± 3.1; 
p = 1 × 10−7) were significantly decreased by the replace-
ment of the double-pigtail stent with a PSS (p*). In group 2, 
the urinary scores were significantly different from those of 
baseline (p**). At Day 15 post-placement, the urinary and 
pain scores for the patients with PSS implants in group 2 
were not significantly different from those of patients with 
PSS implants in group 1 (p***). At baseline, the urinary 
scores and pain scores in group 1 were not significantly dif-
ferent from those of control group (p****).
Discussion
Double-pigtail stents are frequently implanted in urologi-
cal practice, to drain urine. The PSS described here uses 
the same mode of drainage in patients with obstructions. 
Whether the obstruction is due to a stone, an ureteropelvic 
junction syndrome, or ureteral stenosis, the upper, unmodi-
fied part of the stent facilitates the passage of urine around 
Table 2  Results of questionnaires
For urinary tract symptoms, all questions in USSQ were used
p* for comparisons between PSS and baseline (double-pigtail stent) in group 1
p** for comparisons between PSS and baseline (no stent) in group 2
p*** for comparisons between the two groups, for the PSS




















Frequency 3.7 ± 1.3 2.8 ± 1.1 0.005 1.9 ± 0.9 2.8 ± 1.0 3 × 10−7 0.87 4.0 ± 1.2 0.52
Nocturia 3.8 ± 1.1 2.8 ± 1.2 1 × 10−4 2.2 ± 0.9 2.9 ± 1.0 3 × 10−5 0.52 3.4 ± 1.4 0.45
Urgency 3.2 ± 1.2 2.4 ± 1.0 0.01 1.4 ± 0.8 2.0 ± 1.0 2 × 10−4 0.17 3.2 ± 1.3 0.95
Urge incontinence 2.0 ± 0.9 1.8 ± 0.8 0.46 1.1 ± 0.5 1.4 ± 0.8 0.006 0.03 1.5 ± 0.8 0.15
Non-urge incontinence 1.8 ± 0.09 1.1 ± 0.3 0.004 1.2 ± 0.6 1.3 ± 0.8 0.48 0.14 1.5 ± 0.8 0.46
Incomplete emptying 3.0 ± 1.2 1.8 ± 0.9 3 × 10−5 1.2 ± 0.6 1.8 ± 1.0 2 × 10−6 0.99 2.5 ± 1.2 0.32
Urethral pain 3.9 ± 1.3 1.8 ± 1.1 5 × 10−8 1.1 ± 0.3 1.7 ± 0.8 8 × 10−6 0.70 3.4 ± 1.1 0.24
Hematuria 2.8 ± 1.4 1.6 ± 0.8 6 × 10−4 1.2 ± 0.5 1.7 ± 1.0 7 × 10−5 0.49 2.6 ± 1.8 0.81
Hematuria amount 2.1 ± 0.8 1.6 ± 0.8 0.01 1.1 ± 0.4 1.5 ± 0.7 0.001 0.62 2.1 ± 1.4 0.96
Interference in life 3.8 ± 1.0 2.3 ± 0.9 3 × 10−5 1.2 ± 0.6 1.7 ± 0.8 6 × 10−4 0.02 3.5 ± 1.4 0.57
Quality-of-life impact 5.3 ± 2.0 3.8 ± 1.6 7 × 10−4 1.7 ± 1.0 3.1 ± 1.5 2 × 10−7 0.08 5.6 ± 1.3 0.54
Total score 35.2 ± 7.5 23.6 ± 5.4 2 × 10−6 15.3 ± 5.6 21.9 ± 6.1 5 × 10−10 0.24 33.3 ± 7.3 0.50
Pain
Pain 23 (95.8 %) 13 (54.2 %) 0.002 16 (29.1 %) 0.04 9 (90 %) 0.51
Pain while passing urine 12 (50.0 %) 4 (16.7 %) 0.03 2 (3.6 %) 0.07 6 (60.0 %) 0.71
Painkillers 3.6 ± 1.3 2.0 ± 1.2 2 × 10−6 1.3 ± 1.9 0.28 2.8 ± 1.8 0.65
Visual analog scale for pain 5.9 ± 2.8 1.8 ± 2.0 3 × 10−5 1.7 ± 1.0 0.31 5.1 ± 2.9 0.46
Total score 11.0 ± 3.9 4.9 ± 3.1 1 × 10−7 4.0 ± 2.8 0.20 9.9 ± 4.3 0.49
Effect on work
Effect on work 3.5 ± 1.5 1.8 ± 1.0 2 × 10−5 1.5 ± 1.0 0.15 3.7 ± 1.3 0.67
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the obstacle. In our view, if the obstruction is located in 
the upper part of the ureter, the rest of the ureter is likely 
to be healthy and does not require drainage with a stent. 
The part of the stent in the bladder is, thus, of no use in 
such conditions, and its presence may provoke secondary 
effects. It has been suggested that pelvic symptoms could 
be decreased by reducing the amount of material in the 
bladder [3]. The replacement of the bladder loop with a fine 
suture results in the presence of only tiny amounts of mate-
rial in the bladder. Only the suture should cross the junction 
between the ureter and the bladder and float in the blad-
der itself (Fig. 2). The replacement of the lower part of the 
stent with a suture, resulting in the absence of an internal 
channel, probably also limits renal reflux.
Stents of several sizes, forms, and compositions have 
been studied, with the aim of reducing these symptoms. 
A short bladder loop seems to be preferable to a long loop 
extending throughout the bladder [7, 8]. The replacement 
of the bladder loop by a more flexible loop has no effect 
[9, 10]. Decreasing the diameter of the stent from 6 to 4.8F 
also has no effect [10]. The beneficial effects or replac-
ing the bladder loop by a collection of loop [3, 11] or by a 
thinned tail with a diameter of 3F [3, 12] remains a matter 
of debate.
Joshi et al. [5] obtained a score of 14.9 for the control 
group without stent. We obtained a score of 15.3 for such 
patients. Patients with a double-pigtail stent had urinary 
symptom scores of about 28 [5]. This score was about 30 
in a subsequent study of 116 patients [9]. Damiano, Gianar-
ini, and Davenport reported scores of about 27, 30, and 32, 
respectively [8, 10, 13]. We obtained a score of 35.2 for 
such patients. The score of our control group is 33.3 and 
was not significantly different than group 1 at baseline. The 
PSS decreased the total score from 35.2 to about 23, and 
this results confirm those of our retrospective study [4]. 
Few studies have reported a significant decrease in urinary 
symptoms. In a meta-analysis, Lamb noted that alpha-
blockers decreased scores [14]. Kawahara [11] reported 
that the Polaris Loop® caused fewer symptoms in a group 
of 25 patients, but this was not confirmed in the series 
reported by Lingeman [3]. Lee [7] found that correct stent 
positioning was more important than drug prescription.
The urinary and pain scores linked to the PSS were not 
significantly different for the patients of the two groups. 
Thus, the scores for group 1 do not seem to be the conse-
quence of excessive enthusiasm for the PSS following poor 
tolerance of the double-pigtail stent.
Despite the clear improvement observed with PSS, the 
patients still had symptoms statistically different from their 
normal state. It seems that some symptoms decrease with 
time (dysuria, hematuria), but the general tolerance remains 
unchanged [15]. However, about 9 months are required to 
observe a significant decrease in urinary symptoms [16]. 
Even with PSS, duration of stenting must be as short as 
possible.
The stent is implanted to ensure the correct drain-
age of urine. The drainage mediated by the double-pigtail 
stent has been described previously. In normal ureters, the 
urine passes between the stent and the ureter wall, rarely 
through the holes. In ureters that are compromised or have 
a reduced diameter, the urine passes through the holes and 
the internal channel. The bladder loop seems to play no 
role in urine flow [17]. Finally, the diameter of the stent (7 
or 3F) has no effect on the efficacy of urine flow [18]. In 
cases in which the lower ureter is healthy, we can confirm 
the normal flow of urine around the PSS.
Three of the PSS had to be withdrawn under ureter-
oscopy, because the sutures were cut too short and had 
migrated into the ureter. In these three cases, the PSS gave 
effective renal drainage. Stent removal through the ureter 
was easy without the further enlargement of meatus. Fol-
lowing these observations, in male patients, we keep a long 
suture so that the PSS length is 30 cm. In women, we cut 
the sutures at the urethral meatus. However, we believe 
that the obstruction must be bypassed by a segment of rigid 
stent and not by the suture. At the beginning of our expe-
rience, we have observed one migration of the suture into 
the ureter when the obstruction was bypassed by the suture 
only. If the ureter is healthy, sutures have not been observed 
to migrate up the ureter.
Fig. 2  Appearance of the ureteral meatus. a Inflamed meatus around the double-pigtail stent. b Punctiform meatus immediately after PSS 
implantation. c Dilated meatus 1 month after PSS implantation
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We felt that it was important to create a device hav-
ing a perfect profile. It is possible that a straight segment 
of the ureter better tolerates the stent section and ureteral 
irritation in the region below the tail induces flank pain. 
PSS without the profiled tail has been used since Decem-
ber 2010 and has greatly reduced bladder symptoms. But 
frequent anterior flank discomfort seemed to be due to 
irritation caused by the lower part of the stent, which was 
sectioned manually and was unmodified. Because of flank 
pain, we rarely used this stent for 2 years. In 1994, Ponsot 
[19] and, in 1995, Dauleh [20] described a new stent proto-
type respectively in eight and three patients. The lower loop 
was replaced by a fine strong nylon loop to increase blad-
der tolerance [19] or prevent natural anti-reflux [20]. But 
no further study was published.
In December 2012, since the creation of the sculpted and 
profiled tail, flank tolerance seems to have been improved. 
Ureteral irritation in the region below the tail may be 
Fig. 3  Dilation of the ureter 
1 month after PSS implanta-
tion. a PSS sutures in the pelvic 
ureter. b PSS sutures in the 
lumbar ureter
Fig. 4  Patient with left renal 
stone and PSS. a Appearance 
of the PSS and the stone on X 
ray. b Dilated ureter on CT scan 
1 month after PSS implantation
Table 3  Diameter of the pelvis and the ureter on CT scan in patients 
with short PSS and proximal stone
The measurements of diameters are in mm
a Section with polyurethane stent alone
b Section with suture alone
PSS side Contralateral 
side
p
Number of CT scan ana-
lyzed
35
Time before CT scan (days) 44.9 ± 28.0
Right side 20
Pelvis dilation 37.5 %
Pelvisa 16.6 ± 6.9 6.6 ± 3.7 2 × 10−6
Upper lumbar uretera 9.1 ± 1.8 3.1 ± 0.5 9 × 10−8
Lower lumbar ureterb 9.0 ± 2.3 3.6 ± 1.2 1 × 10−13
Iliac ureterb 7.2 ± 1.7 3.1 ± 0.6 8 × 10−11
Pelvic ureterb 6.4 ± 1.6 4.0 ± 0.8 1 × 10−10
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milder than that in the unmodified section. The thinning of 
the lower end of the device seems to limit the snagging of 
the stent during breathing movements (Fig. 1c). Industrial 
manufacturers will be required to produce such a device. 
The suture could then be integrated into the stent, emerging 
at the extreme end of the tail. In this way, stent tolerance 
might be improved.
We developed the PSS as a means of decreasing urinary 
symptoms, but we discovered fortuitously that it had other 
surprising properties, probably due to the simple presence 
of the sutures in the ureter.
Firstly, about 1 month after PSS implantation, we 
observed in all cases of ureteroscopy clear dilation of 
the ureter intubated with the sutures (Fig. 3). It has been 
showed that preoperative stenting is effective for dila-
tion of the ureter in preparation for ureteroscopy [21, 
22] and insertion of an ureteral access sheath [22]. Three 
weeks seemed sufficient for dilation [21]. With the PSS, 
no patient required active dilation of the ureteral meatus 
at ureteroscopy. The prior implantation of a PSS could be 
used to prepare the ureter for the insertion of a sheath for 
flexible ureteroscopy without excessive discomfort. This 
could facilitate the introduction of a large ureteral access 
sheath (14/16F) for ureteroscopic treatment of large stone 
[23]. We believe that dilation was probably induced by the 
sutures. Ureteroscopy, fluoroscopic, and CT scan imaging 
allowed measuring the degree of dilation (Fig. 4). To clar-
ify our endoscopic observations, we measured the diam-
eters of the pelvis and the ureter drained by PSS and we 
compared them with the diameters of the same contralat-
eral segments. Table 3 shows the results for 35 patients of 
this study with short PSS and only proximal stone.
Secondly, after extracorporeal shockwave lithotripsy, the 
stone fragments gradually slid down the PSS sutures, with-
out renal colic. Sutures behaves like a “stone’s toboggan” 
(Fig. 5). Ureteral dilation might accelerate the removal of 
stone fragments.
We believe that the use of a double-pigtail stent should 
no longer be considered the only way to drain the ureter. 
Instead, the form of the stent should depend on the patient’s 
disease. For example, in cases of non-obstructive kidney 
stones suitable for treatment by extracorporeal shockwave 
lithotripsy, we now use a stent reduced to a suture attached 
to a simple renal pigtail [4].
Conclusion
The PSS significantly decreases urinary symptom and pain 
scores and constitutes a medical advance in the domain of 
ureteral stent tolerance. We observed unexpected dilation 
of the ureter by the sutures. We encourage and are con-
vinced that multicenter studies with possibly a randomized, 
controlled trial would confirm the improvement in patient’s 
quality of life reported here. These studies would make it 
possible to enlarge the indications for the PSS and would 
also make it possible to investigate the other properties of 
the ureteral suture.
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Fig. 5  Patient with left ureteral 
stone and PSS. a Appearance 
of the stone along the suture in 
the dilated ureter on CT scan. 
b No ureteral inflammation is 
visible in contact with the stone 
(endoscopic appearance)
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